A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
Clinical trial NCT06892288 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06892288
- Sponsor
- Glycomine, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-09
- Primary completion
- 2026-08-05
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.